CorreGene Appoints Dr. Li Miao as Vice President of Medical Affairs to Accelerate Global Clinical Development of TCR-Based Therapies
CorreGene
Developer of Tumor Immunotherapy and Gene Therapy Technologies
RecentlyBeijing Kerui Biological Technology Co., Ltd. announced that Ms. Li Miao has been appointed as the company's Vice President of Medicine. She will report directly to Dr. Xie Xingwang, CEO of Kerui Bio, and take full responsibility for formulating and executing clinical development strategies and operations for the company’s cell therapy and protein drug pipelines in China and overseas. She will also oversee medical affairs and manage the entire process to ensure efficient project advancement and global expansion.
Vice President of Kerui Biomedical, Li Miao
Ms. Li Miao holds a master's degree in clinical oncology and has undergone systematic and standardized clinical training, possessing extensive experience in clinical diagnosis and treatment in oncology.
Dr. Xie Xingwang
Founder and General Manager of Beijing Kerui Biological Technology Co., Ltd.
Kerui Bio always focuses on the underlying technological innovation of TCR-related therapies. The company is currently in a high-speed development phase, with the first TCR-T cell drug having initiated clinical research. Two cell drugs have entered the IIT clinical trial stage, and the first TCR protein drug has started preclinical research.
At this critical stage of the company's development, the addition of Ms. Li Miao will significantly enhance our core competitiveness in innovative sourcing and clinical development, marking a new phase in the development of Beijing Kerui Biological Technology Co., Ltd., and will also accelerate the realization of its strategic goal to "progress from China’s first innovations to global leadership."
In the future, the team will continue to focus on the development of TCR-T cell therapy drugs and soluble TCR protein drugs, promoting the implementation of safer, more effective, and more accessible solid tumor treatment solutions. We firmly believe that only by deeply integrating scientists' ultimate exploration with clinical developers can we truly rewrite the life trajectories of cancer patients.
Beijing Kerui Biological Technology Co., Ltd. was co-founded by several Peking University alumni and returned overseas students, and is committed to the development of innovative drugs based on T-cell receptors (TCR). Through technological innovation, Kerui Biological has established a systematic TCR R&D platform that addresses a series of technical challenges in TCR cloning and optimization, enabling high-efficiency, large-scale TCR innovative drug development. The independently developed "SMART-TCR®"Affinity Optimization and "CorEngagerTM"T-cell engager platform breaks through the R&D barriers of TCR innovative drugs; a mature process development and analytical quality control industrialization platform accelerates TCR therapy innovation. Relying on R&D and industrialization platforms, the company simultaneously develops two product categories: TCR-T cell therapy and soluble TCR protein drugs, targeting a trillion-dollar market encompassing cancer, chronic infections, and autoimmune diseases."
E.N.D
Article Recommendation (Click on the article title below to open the original):
From the latest report by "People's Daily," see how cell therapy is reshaping the future of medicine
An RNA Drug Approved for Marketing
A Cell Therapy Company Lays Off 90%, Halts Core R&D Projects
Five Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields
$1 Billion! An In Vivo Cell Therapy Company Acquired
A Company in China Completes B+ Round Financing, Focusing on Cell and Gene Therapy Industry
NMPA Approves First Mesenchymal Stromal Cell Drug for Clinical Use
China's First Case of Autism Stem Cell New Drug Approved for Clinical Trials
Statement: Content SourceFor the official use of the company, this article aims at knowledge sharing. All content is for reference only and does not constitute any advice.